Alembic Pharmaceuticals Ltd Q4 FY2025 Concall Summary

Key Takeaways

• Strong Q4, led by international: Revenue grew 17% YoY to ₹1,770 cr, with US Generics up 20% and Ex-US up 43%, while India grew a steady 8%.
• Gross margin reset to ~70%: Product mix from high-volume, lower-margin launches pushed gross margins down from 73-74%; management’s internal target is to hold around 70% going forward.
• Inventory buildup is launch-driven, not tariff-driven: Inventories rose due to multiple US launches, day-one stocking requirements, and one delayed launch; management explicitly denied any link to tariff pre-buying.
• EBITDA margin recovery story is operating leverage: Four under-utilized facilities (two injectables) are the primary drag; as capacity utilization rises and R&D spend optimizes from 14% to 8-9%, margins should climb back toward 18-20%.
• What to watch next quarter: Whether the 4-5 planned Q1 US launches materialize and begin drawing down the elevated inventory, and whether gross margins stabilize near the 70% floor as the launch mix evolves.

US Generics: Launches, Volume & the Margin Tradeoff

• Volume-led growth strategy: US Generics grew 20% in Q4 (₹508 cr) driven by volume and new product launches; FY26 growth is guided at mid-to-high teens (~15%), depending on launch cadence and price erosion.
• QoQ dip explained: Q4 US revenue was lower sequentially because Q3 benefited from one-time buy opportunities and products in shortage, plus day-one stocking that pulled demand forward.
• 4-5 launches planned for Q1: Management expects this pace to sustain momentum into FY26.
• Gross margin is the cost of that volume: High-volume products carry lower realizations and margins, which management accepts as part of building scale; the internal target is to maintain gross margins around 70%.
• Inventory tied to launch execution: Day-one launches require carrying a couple of months of inventory; one particular launch got pushed back, leaving excess stock that will be worked down as the year progresses.
• Complex injectables on the horizon: Limited-competition injectable launches are expected toward the end of FY26 or early FY27, which could improve the margin mix if they materialize on time.

Pranav Amin: "I said in the call earlier that semaglutide we are a little late for the U.S. launch. We don't have the day one, but we will be there in some of the ROW markets, whereas Tirzepatide is the one we hope to be there on day one."

International ex-US & API: The Growth Accelerators

• Ex-US (ROW) surged 43% in Q4 to ₹375 cr, with FY26 growth guided at 12-15%; management sees continued momentum across all three international businesses.
• API returned to growth at +4% in Q4 after degrowing 9% for the full year; FY26 guidance is ~10% growth, though Chinese competition remains a pricing headwind on existing products.
• Animal Health delivered 19% Q4 growth and 21% for the full year, backed by strong brands and new launches.
• Semaglutide opportunity is ROW, not US: Management acknowledged being late for the US day-one launch but confirmed participation in select ROW markets.
• Tirzepatide is the day-one bet: Management hopes to be present on day one across all markets, though filing is still pending and the NCE-1 appointed date has not yet occurred.

India Business: Steady, with a Double-Digit Ambition

• India grew 8% in Q4 (₹545 cr) and 6% for FY25 (₹2,339 cr); key growth drivers were gynecology, antidiabetic, ophthalmology, and dermatology.
• Anti-infective and cough & cold rebounded: Two large segments that had struggled due to market slowdown grew 7% and 11% respectively in Q4.
• FY26 target is double-digit growth: Management has a plan in place to drive 10%+ growth for the full year, with the MR count holding steady at ~5,500 (only a hundred-odd additions planned).
• Anti-infective base effect moderating: The antibiotic portfolio had a significant ramp-up from 2023; current weakness reflects that base effect normalizing, and both markets should start growing from here.

Margin Structure & the Operating Leverage Thesis

• Gross margin declined to ~70%+ from 73-74%, driven entirely by product mix: quarters with high-volume, lower-realization launches compress the gross margin line.
• Management is not alarmed: The internal target is about 70% gross margin, and all new launches, price erosion, and higher volumes being pushed will keep it around that level; no explicit FY26 gross margin guidance was given.
• EBITDA margin recovery hinges on two levers: (1) increasing capacity utilization in four new facilities, two of which are relatively newer injectables not fully utilized, and (2) optimizing R&D spend from 14% of sales toward 8-9%.
• R&D spend is project-driven: Q4 R&D was 9% of sales (₹151 cr); FY25 was ₹522 cr; FY26 guidance is ₹600-650 cr, depending on how projects progress.
• CAPEX cycle is largely behind: FY25 saw heavy CAPEX including the Pithampur formulation facility (~₹200 cr cumulative), a new peptide block at API 2, and an additional injectables line at F3; FY26 CAPEX is guided at ₹400-450 cr, mostly maintenance and spillover.
• Working capital should normalize: Receivable days rose slightly due to last-quarter sales and new launches but are expected to return to ~75 days in the next few quarters; short-term borrowings shot up on inventory-driven working capital needs and should reduce as cash flow from inventory release and profit comes through.

Pranav Amin: "How do we go back up to like 18%-19%-20% kind of EBITDA levels? And I didn't give a timeframe, but how that will happen is, we have these three new facilities, four new facilities, out of it two of them are relatively newer injectables. As we get more capacity utilization in those facilities, as we start getting more volumes out of those facilities, that will automatically give a lot of operating leverage because these are not fully utilized right now."

Tariffs: A Macro Risk, Not an Alembic-Specific One

• Management sees tariffs as an industry-wide issue: Only about 10% of US generic volumes can be manufactured domestically; the rest would face a huge shortfall if drastic tariff steps were taken.
• No Alembic-specific contingency was offered: When asked about fallback options given Alembic has no US plant, management deflected to the macro argument that governments are trying to work it out and no peer has sufficient US capacity.
• Inventory buildup is explicitly not tariff-driven: Management stated the inventory is from launches, including one that got pushed back, and denied any connection to tariff pre-buying.

Pranav Amin: "…only about 10% of the volumes can be manufactured in the U.S. So the rest of it is, going to be a huge shortfall."

Pipeline & Complex Products: The Next Leg

• Peptide manufacturing block is part of completed CAPEX; filings will be done, but products will take time to reach market.
• Bosutinib timeline is uncertain: Management said it may come in FY26 but cited a technical issue and declined to commit.
• Riociguat (Adempas) is not a day-one opportunity: Management confirmed they are not there on day one and did not provide timing or revenue expectations, calling it a "decent size" product.
• Limited-competition injectables are expected toward the end of FY26 or early FY27, representing a potential margin tailwind if they launch on schedule.

Guidance & Commitments

Key Metrics